{"id":"W4317212031","doi":"10.2217/frd-2022-0015","title":"The Effects of Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva: A Plain Language Summary","year":2023,"lang":"en","type":"article","venue":"Future Rare Diseases","topic":"Heterotopic Ossification and Related Conditions","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hospital for Sick Children; University of Toronto; University Health Network","funders":"Daiichi Sankyo Europe; UCB Pharma; Incyte; BioCryst; Mead Johnson Nutrition; International Fibrodysplasia Ossificans Progressiva Association; Ultragenyx Pharmaceutical; Ipsen; Regeneron Pharmaceuticals; Pfizer","keywords":"Fibrodysplasia ossificans progressiva; Clinical trial; Medicine; Heterotopic bone; Myositis ossificans; Physical therapy; Bone formation; Dentistry; Surgery; Heterotopic ossification; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002540622,0.0006363431,0.002556851,0.0007054402,0.0003066343,0.001908269,0.0009585379,0.001867497,0.01138827],"category_scores_gemma":[0.005632206,0.0002462782,0.002554842,0.0008860792,0.0004388432,0.001496776,0.0004218467,0.002686576,0.002203759],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008453336,"about_ca_system_score_gemma":0.001414819,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009646763,"about_ca_topic_score_gemma":0.002225185,"domain_scores_codex":[0.9987999,0.0004860972,0.0003836766,0.0000699239,0.0001940983,0.00006635703],"domain_scores_gemma":[0.9953453,0.00223506,0.001429276,0.00008219796,0.0007173733,0.0001907485],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.02166296,0.0006285372,0.002063749,0.1127798,0.001886741,0.0008164208,0.0002482052,0.0004488527,0.002304804,0.002129351,0.220044,0.6349866],"study_design_scores_gemma":[0.03264777,0.02284316,0.02171145,0.1090021,0.009409442,0.003795725,0.0008226146,0.0006966744,0.002037243,0.003986293,0.7927836,0.0002638995],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"other","genre_scores_codex":[0.007069143,0.9356372,0.0004477862,0.035711,0.006733507,0.0007852498,0.002991106,0.00007336423,0.01055158],"genre_scores_gemma":[0.05663988,0.8283737,0.002936479,0.07710445,0.01894394,0.002044518,0.003748496,0.00006900348,0.01013957],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.01138827,"threshold_uncertainty_score":0.03809756,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.002490181814365724,"score_gpt":0.2267368739953984,"score_spread":0.2242466921810327,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}